• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/21/25 4:15:15 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    8-K
    0001520262falseAlkermes plc.00015202622025-05-212025-05-21

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 21, 2025

    ALKERMES PUBLIC LIMITED COMPANY

    (Exact name of registrant as specified in its charter)

     

    Ireland

     

    001-35299

     

    98-1007018

    (State or other jurisdiction

     

    (Commission

     

    (IRS Employer

    of incorporation)

     

    File Number)

     

    Identification No.)

     

     

     

     

     

     

    Connaught House, 1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Address of principal executive offices)

     

    Registrant's telephone number, including area code: + 353-1-772-8000

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Ordinary shares, $0.01 par value

     

    ALKS

     

    Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

     

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 21, 2025, at the 2025 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for issuance thereunder by 4,250,000 (the plan as so amended, the “2018 Plan”).

    The principal features of the 2018 Plan are summarized on pages 57-61 of the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 7, 2025. That summary and the foregoing description are not intended to be complete and are qualified in their entirety by reference to the full text of the 2018 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On May 21, 2025, the Company held its Annual Meeting. The final voting results for the Annual Meeting are as follows:

    1.
    By separate resolutions, shareholders elected the following directors, each to serve on the Company’s board of directors (the “Board”) for a one-year term until the Company’s 2026 annual general meeting of shareholders, with the votes cast as follows:

    For:

    Against:

    Abstain:

    Broker Non-Votes:

    Shane M. Cooke

    144,556,374

    704,862

    849,622

    8,347,962

    Richard B. Gaynor, M.D.

    142,882,295

    2,380,214

    848,349

    8,347,962

    Cato T. Laurencin, M.D., Ph.D.

    140,933,916

    4,231,803

    945,139

    8,347,962

    Nancy S. Lurker

    144,523,454

    731,150

    856,254

    8,347,962

    Brian P. McKeon

    144,418,372

    842,035

    850,451

    8,347,962

    Richard F. Pops

    141,115,166

    4,139,634

    856,058

    8,347,962

    Nancy L. Snyderman, M.D.

    138,701,039

    5,900,596

    1,509,223

    8,347,962

    Frank Anders Wilson

    144,341,353

    919,211

    850,294

    8,347,962

    Christopher I. Wright, M.D., Ph.D.

    140,630,049

    4,543,496

    937,313

    8,347,962

     

    2.
    Shareholders approved, in a non-binding, advisory vote, the compensation of the Company’s named executive officers, with the votes cast as follows: 143,326,743 votes for; 1,891,000 votes against; 893,115 votes abstaining; and 8,347,962 broker non-votes.
    3.
    Shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and authorized, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration, with the votes cast as follows: 152,615,011 votes for; 990,750 votes against; and 853,059 votes abstaining.
    4.
    Shareholders approved the 2018 Plan, with the votes cast as follows: 126,994,261 votes for; 18,252,782 votes against; 863,815 votes abstaining; and 8,347,962 broker non-votes.
    5.
    Shareholders renewed Board authority to allot and issue shares under Irish law, with the votes cast as follows: 151,248,531 votes for; 2,359,603 votes against; and 850,686 votes abstaining.
    6.
    Shareholders renewed Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law, with the votes cast as follows: 149,705,078 votes for; 3,870,144 votes against; and 883,598 votes abstaining.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    2


     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

     

     

     

    10.1

     

    Alkermes plc 2018 Stock Option and Incentive Plan, as amended.

    104

     

    Cover page interactive data file (embedded within the Inline XBRL document).

     

     

    3


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ALKERMES PLC

     

     

    Date: May 21, 2025

    By:

     

    /s/ David J. Gaffin

     

     

     

    David J. Gaffin

     

     

     

    Secretary

     

    4


    Get the next $ALKS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of c

      6/2/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

      – Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the c

      6/2/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

      – Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study – – New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented – DUBLIN, May 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 developm

      5/29/25 7:24:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:39:56 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:37:23 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I covered exercise/tax liability with 1,924 units of Ordinary Shares and converted options into 8,013 units of Ordinary Shares, increasing direct ownership by 42% to 20,505 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/2/25 4:34:11 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

      6/17/25 7:46:56 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Alkermes Plc with a new price target

      Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

      5/28/25 8:55:31 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

      RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00

      3/13/25 7:24:22 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    SEC Filings

    See more
    • Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alkermes plc. (0001520262) (Filer)

      5/21/25 4:15:15 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Alkermes plc

      SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

      5/13/25 10:23:10 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Alkermes plc

      DEFA14A - Alkermes plc. (0001520262) (Filer)

      5/12/25 5:03:55 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alkermes plc

      SC 13G - Alkermes plc. (0001520262) (Subject)

      11/14/24 1:22:34 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/12/24 1:28:21 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/8/24 10:46:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Financials

    Live finance-specific insights

    See more
    • Alkermes plc Reports First Quarter 2025 Financial Results

      —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

      5/1/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report First Quarter Financial Results on May 1, 2025

      DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc  Alkermes plc is a global biopharmaceutic

      4/17/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

      —    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —    GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — —    ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025  /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.

      2/12/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

      DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

      3/7/24 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

      —  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.  "Dr. Loew's deep knowledge of the oncology fi

      6/1/23 4:01:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care